Revenue Growth and Financial Performance
BrainsWay reported a 26% year-over-year increase in revenue to $10.5 million for the third quarter of 2024. The company generated positive quarterly net income for the fourth consecutive quarter and positive adjusted EBITDA and cash flow from operations for the fifth consecutive quarter.
Strong Cash Position and Strategic Financing
BrainsWay reported $48.4 million in cash as of September 30, 2024, and completed a strategic private investment equity financing with Valor Equity Partners for approximately $20 million, resulting in a pro forma cash position of approximately $68.4 million.
Guidance and Profitability Outlook
The company increased its full-year 2024 revenue guidance to a range of $40 million to $41 million, representing growth of 26% to 29% over 2023 revenue. It also anticipates generating operating income of 3% to 4% and adjusted EBITDA of 10% to 11% for the full year 2024.
Expansion of Global Distribution
BrainsWay expanded its global distribution and sales network, with placements of 15 new Deep TMS systems in Taiwan and South Korea. The company is also seeking additional regulatory approvals and reimbursement coverage expansions.
R&D and Clinical Trials
The company reported that its multicenter clinical trial for an accelerated treatment protocol for its Deep TMS system to treat major depressive disorder is fully underway.